PROSPECTS OF TARGET AN-TICYTOKINE THERAPY APPLI-CATION BASED ON THE CHE-LATE NANOCOMPLEXES

Cytokines have a leading role in the development of inflammatory reactions. In the ophthalmology, proinflammatory cytokines such as IL-1β, IL-6, TNF-α, which are the main mediators of the development, progression and therapeutic outcome of not only inflammatory diseases (uveitis, ophthalmic herpes), but also pathologies of the age-related diseases (cataract and glaucoma), where cytokines act as mediated pathogenetic factors, are intensively studied. Despite the validity and prospects of anti-cytokine therapy, in ophthalmic practice it is hampered by the high cost, as well as the limited effectiveness of drugs created by the principle of monoclonal antibodies and aimed only at one protein receptor. Alternative may be multi-target anti-cytokine therapy using an innovative preparation MSC-428 based on chelate nanocomplexes. The active substance MSC-428 is a low molecular weight chelating coordination compound in which the central atom of a heavy metal, mercury, is bound to two molecules of L-cysteine. The complex compound has a tetrahedral structure in which the carboxyl groups located on the periphery of the molecule (anchor molecules) allow interaction with amino groups of proteins, affecting their tertiary structure (conformation).The ultra-small size provides integration into the active site of the cell receptor, and the presence of the heavy metal atom, predetermines conformational changes in the spatial structure of the receptor protein. The aim of the investigation was to study the effectiveness of multi-target anti-cytokine therapy using the innovative preparation MSC-428 by elucidating the functional and phenotypic changes in the subpopulations of blood lymphocytes in patients with various pathologies of the eye during treatment with this drug.